Michael D Ezekowitz
Overview
Explore the profile of Michael D Ezekowitz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
186
Citations
21176
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ezekowitz M, Alameh I, Kamareddine M
JACC Adv
. 2024 Aug;
3(8):101118.
PMID: 39105111
No abstract available.
2.
Johnson L, Jiang Y, Luu J, Van Gelder I, Atzema C, Conen D, et al.
Eur Heart J
. 2024 Jun;
45(26):2336-2340.
PMID: 38833334
No abstract available.
3.
Shah S, van Walraven C, Jeon S, Boscardin J, Hobbs F, Connolly S, et al.
Circ Cardiovasc Qual Outcomes
. 2024 Mar;
17(4):e010269.
PMID: 38525596
Background: Patients with atrial fibrillation have a high mortality rate that is only partially attributable to vascular outcomes. The competing risk of death may affect the expected anticoagulant benefit. We...
4.
Ezekowitz M, Kamareddine M
Circulation
. 2023 Aug;
148(12):947-949.
PMID: 37621202
No abstract available.
5.
Carlisle M, Shrader P, Fudim M, Pieper K, Blanco R, Fonarow G, et al.
Heart Rhythm O2
. 2023 Jan;
3(6Part A):621-628.
PMID: 36589908
Background: Oral anticoagulation (OAC) reduces the risk of thromboembolic events in patients with atrial fibrillation (AF); however, thromboembolism (TE) still can occur despite OAC. Factors associated with residual risk for...
6.
Taoutel R, Ezekowitz M, Chaudhry U, Weber C, Hassan D, Gracely E, et al.
Int J Cardiol Heart Vasc
. 2022 Oct;
43:101130.
PMID: 36246771
Direct-acting oral anticoagulants (DOACs) represent the standard for preventing stroke and systemic embolization (SSE) in patients with atrial fibrillation (AF). There is limited information for patients ≥ 80 years. We...
7.
Mar P, Gopinathannair R, Gengler B, Chung M, Perez A, Dukes J, et al.
Circ Arrhythm Electrophysiol
. 2022 May;
15(6):e007956.
PMID: 35622425
Oral anticoagulants (OACs) are medications commonly used in patients with atrial fibrillation and other cardiovascular conditions. Both warfarin and direct oral anticoagulants are susceptible to drug-drug interactions (DDIs). DDIs are...
8.
Liu H, Ezekowitz M, Columbo M, Khan O, Martin J, Spahr J, et al.
Trials
. 2021 Sep;
22(1):603.
PMID: 34493311
Background: The World Health Organization declared the outbreak of SARS-CoV-2 a pandemic on February 11, 2020. This organism causes COVID-19 disease and the rapid rise in cases and geographic spread...
9.
Pol T, Hijazi Z, Lindback J, Oldgren J, Alexander J, Connolly S, et al.
Cardiovasc Res
. 2021 Aug;
118(9):2112-2123.
PMID: 34358298
Aims: Atrial fibrillation (AF) is associated with higher mortality. Biomarkers may improve the understanding of key pathophysiologic processes in AF that lead to death. Using a new multiplex analytic technique,...
10.
Chaudhry U, Ezekowitz M, Gracely E, George W, Wolfe C, Harper G, et al.
Am J Cardiol
. 2021 Jun;
152:69-77.
PMID: 34162485
Low dose direct acting oral anticoagulants (LDDOACS) were approved for elderly atrial Fibrillation (AF) patients with limited information. A retrospective analysis collecting baseline characteristics and outcomes in AF patients ≥...